A Comparison of Denosumab Versus Zoledronic Acid for the Prevention of Skeletal-Related Events in Breast Cancer Patients with Bone Metastases

被引：1
|
作者：
Stopeck, A.
de Boer, R.
Fujiwara, Y.
Lichinitser, M.
Tonkin, K.
Yardley, D.
Fan, M.
Jiang, Q.
Jun, S.
Dansey, R.
Braun, A.
机构：
[1] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA
[2] Western Hosp, Footscray, Vic, Australia
[3] Natl Canc Ctr, Tokyo, Japan
[4] Blokhin Canc Res Ctr, Moscow, Russia
[5] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[6] Sarah Cannon Res Inst, Nashville, TN USA
[7] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：490S / 490S
页数：1
相关论文
共 50 条
  • [1] A COMPARISON OF DENOSUMAB VERSUS ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN BREAST CANCER PATIENTS WITH BONE METASTASES
    Fujiwara, Yasuhiro
    Stopeck, Alison
    de Boer, Richard
    Lichinitser, Mikhail
    Tonkin, Katia
    Yardley, Denise
    Fan, Michelle
    Jiang, Qi
    Jun, Susie
    Dansey, Roger
    Braun, Ada
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 12 - 12
  • [2] Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics
    Lipton, A.
    Fizazi, K.
    Stopeck, A. T.
    Henry, D. H.
    Smith, M. R.
    Shore, N.
    Martin, M.
    Vadhan-Raj, S.
    Brown, J. E.
    Richardson, G. E.
    Saad, F.
    Yardley, D. A.
    Zhou, K.
    Balakumaran, A.
    Braun, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 53 : 75 - 83
  • [3] COMPARATIVE BUDGET IMPACT OF FORMULARY INCLUSION OF ZOLEDRONIC ACID AND DENOSUMAB FOR PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES
    Bell, M. J.
    Miller, J. D.
    Namjoshi, M.
    Russell, M. W.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A159 - A159
  • [4] The skeletal-related events of denosumab versus zoledronic acid in patients with bone metastases: A meta-analysis of randomized controlled trials
    Zhang, Zhicai
    Pu, Feifei
    Shao, Zengwu
    [J]. JOURNAL OF BONE ONCOLOGY, 2017, 9 : 21 - 24
  • [5] Denosumab In the Prevention of Skeletal-Related Events in Patients with Bone Metastases from Solid Tumours
    Scott, Lesley J.
    Muir, Victoria J.
    [J]. DRUGS, 2011, 71 (08) : 1059 - 1069
  • [6] Denosumab for the prevention of symptomatic skeletal events (SSEs) in patients with bone-metastatic breast cancer: A comparison with skeletal-related events (SREs)
    Body, J-J.
    von Moos, R.
    Lipton, A.
    Martin, M.
    Diel, I.
    Steger, G.
    Tonkin, K.
    de Boer, R.
    Radcliffe, H-S.
    Niepel, D.
    Stopeck, A. T.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [7] Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients
    Dranitsaris, George
    Hatzimichael, Eleftheria
    [J]. SUPPORTIVE CARE IN CANCER, 2012, 20 (07) : 1353 - 1360
  • [8] COST-EFFECTIVENESS OF DENOSUMAB VERSUS ZOLEDRONIC ACID (ZA) FOR THE PREVENTION OF SKELETAL-RELATED EVENTS (SRE) IN PATIENTS WITH BONE METASTASES FROM SOLID TUMORS IN THE NETHERLANDS
    Lothgren, M.
    Bracco, A.
    Lucius, B.
    Northridge, K.
    Halperin, M.
    Macarios, D.
    Chung, K.
    Danese, M. D.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A455 - A455
  • [9] DENOSUMAB VERSUS ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH BONE METASTASES SECONDARY TO SOLID TUMOURS: AN INTEGRATED ANALYSIS OF THREE PHASE 3 STUDIES
    Stopeck, A. T.
    Richardson, G.
    Siena, S.
    Lipton, A.
    Brown, J.
    Fizazi, K.
    Henry, D.
    Saad, F.
    Ke, C.
    Braun, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : S8 - S8
  • [10] ZOLEDRONIC ACID IS COST EFFECTIVE FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN PATIENTS WITH PROSTATE CANCER AND BONE METASTASES IN FRANCE AND GERMANY
    Meijboom, Marjan
    Botteman, Marc F.
    Kaura, Satyin
    [J]. JOURNAL OF UROLOGY, 2009, 181 (04): : 295 - 295
12345